Sanofi Admits Defeat for Myasthenia Gravis Candidate, Drops Phase III Trial

Sanofi is discontinuing its Phase III study of tolebrutinib, an investigational BTK inhibitor for myasthenia gravis (MG), the company announced Friday in its full-year 2022 financial report.